Drug Profile

NTS 231

Alternative Names: NTS-231

Latest Information Update: 12 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator NUTSHELL Therapeutics
Class Antineoplastics; Small molecules
Mechanism of Action NF-E2-related factor 2 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Solid tumours

Most Recent Events

22 Oct 2025 Pharmacokinetics and adverse events data from preclinical trials in Solid tumours at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2025 (AACR-NCI-EORTC-2025)
22 Oct 2025 Nutshell Therapeutics plans to file an IND application for Solid tumours in 2026
22 Oct 2025 Preclinical trials in Solid tumours in China (PO), prior to October 2025 (Nutshell Therapeutics pipeline, November 2025)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com